SCHEMBL440260

SCHEMBL440260

COC(C)C(O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6664987 0.78
SCHEMBL13180924 0.78
SCHEMBL7887917 0.76
SCHEMBL15459382 0.76
SCHEMBL13569499 0.76
SCHEMBL4367545 0.74
SCHEMBL37836 0.74
SCHEMBL5016586 0.74
SCHEMBL15031916 0.74
SCHEMBL16501322 0.74 ALDH1A1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936317-A Method for producing strongly adherent (embossed) films on flexible substrates 巴斯夫欧洲公司 2020-11-13 CN claimed
CN-111936315-A Method for preparing strong adhesive liquid crystal film on flexible substrate 巴斯夫欧洲公司 2020-11-13 CN claimed
WO-2023190758-A1 COMPOSITE TUNGSTEN OXIDE PARTICLES, NEAR-INFRARED-ABSORBING PARTICLE DISPERSION LIQUID, AND NEAR-INFRARED-ABSORBING PARTICLE DISPERSION 住友金属鉱山株式会社 2023-10-05 WO disclosed
US-20210292588-A1 PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT LIQUID CRYSTAL FILMS ON FLEXIBLE SUBSTRATES BASF SE (DE) 2021-09-23 US disclosed
US-20210086545-A1 PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT (EMBOSSED) FILMS ON FLEXIBLE SUBSTRATES BASF SE (DE) 2021-03-25 US disclosed
EP-2667850-A1 MAINTAINING ANTIBODY-BINDING ACTIVITY OF IMMUNOSUPPRESSANT DRUG CONJUGATES Siemens Healthcare Diagnostics Inc. (US) 2013-12-04 EP disclosed
US-8334104-B2 Methods for detection of hydrophobic drugs SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2012-12-18 US disclosed
US-20120237550-A1 Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2012-09-20 US disclosed
WO-2012125856-A1 MAINTAINING ANTIBODY-BINDING ACTIVITY OF IMMUNOSUPPRESSANT DRUG CONJUGATES SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2012-09-20 WO disclosed
EP-2489666-A2 Chemically and chirally pure solifenacin base and its salts Cadila Healthcare Limited (IN) 2012-08-22 EP disclosed
EP-2484681-A1 Chemically and chirally pure gentisate salt of solifenacin Cadila Healthcare Limited (IN) 2012-08-08 EP disclosed
US-20120064546-A1 METHODS FOR DETECTION OF HYDROPHOBIC DRUGS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2012-03-15 US disclosed
US-20110136136-A1 Methods For Detection Of Hydrophobic Drugs SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2011-06-09 US disclosed
US-7910378-B2 Methods for detection of hydrophobic drugs SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2011-03-22 US disclosed
US-20100298371-A1 PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS CADILA HEALTHCARE LIMITED (IN) 2010-11-25 US disclosed
EP-2229387-A1 PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS Cadila Healthcare Limited (IN) 2010-09-22 EP disclosed
EP-2217926-A1 METHODS FOR DETECTION OF HYDROPHOBIC DRUGS Siemens Healthcare Diagnostics Inc. (US) 2010-08-18 EP disclosed
WO-2009087664-A1 PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS CADILA HEALTHCARE LIMITED (IN) 2009-07-16 WO disclosed
WO-2009079374-A1 METHODS FOR DETECTION OF HYDROPHOBIC DRUGS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2009-06-25 WO disclosed
US-20090155929-A1 METHODS FOR DETECTION OF HYDROPHOBIC DRUGS SIEMENS HEALTHCARE DIAGNOSTICS INC., A CORPORATION OF CALIFORNIA (US) 2009-06-18 US disclosed